|
Pharma 50
The Top 50 Pharma Companies — in Brief
The vigorous return of M&A activity to biopharmaceuticals this year begs the question: is more size and scalable efficiencies the best solution to the declining market power of pharmaceuticals in an endlessly restructuring healthcare system? Our latest annual iteration of the Pharma 50 rankings confirms that the answer to this is ‘no’ ...Read more
Pharma 50
The Long Tail: Behind This Year’s Pharma Top 50
Editor-in-Chief William Looney gives his take on the risers, fallers, and new additions to this year’s Pharm Exec Pharma 50 and finds that the size and scale measure to R&D offers little comfort when it comes to the crucial financial relationship between an enterprise’s draught weight and returns on every dollar invested in new drug development
...Read more
Regulatory
What Does ‘Off Label’ Mean in 2014?
Although drug companies make an enormous effort to obtain an FDA approval with a very specific indication, it always comes as a bit of a shock to learn that the medical community is not only using the product for that hard to achieve FDA approval — but also for several other non-approved indications. Tom Norton reports
...Read more
Pharma Gets the Social Media Go-Ahead
Long a subject of concern in the heavily regulated space of pharma marketing, the latest FDA guidance on the use of social media is providing new freedom to explore digital marketing channels.  Read on
to learn more about what the FDA had to say about user-generated content, company blogs and more.
Technology
What Apple’s “HealthKit” Announcement Means to Healthcare
Among the many announcements Apple made earlier this week at its annual World Wide Developer’s Conference, one was of particular interest to the healthcare industry. Apple unveiled “HealthKit”, which is really a developer’s toolbox that allows makers of health and medical devices to more seamlessly integrate their offerings with Apple’s newest mobile operating system, iOS8. Bill Drummy reports ...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence – by downloading this eBook. Read more
New Report
Product Cycle Strategies for Greater Profitability
In this compilation of four in-depth, data-rich reports from Pharmaceutical Executive, you'll learn a new set of metrics allowing companies to align their strategies around the push for greater profitability, putting them on the right track ...Click here to order |
